Aptose Bioscienc Stock Price, News & Analysis

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced it will release financial results for the year and quarter ended December 31, 2021, on March 22, 2022, post-market close. The report will include a corporate update. A conference call is scheduled for the same day at 5:00 PM ET, accessible via dial-in and webcast. Key products in Aptose's pipeline include two oral kinase inhibitors aimed at treating hematologic malignancies, currently undergoing various clinical trials.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022. William G. Rice, Ph.D., Chairman, President, and CEO, will present and host one-on-one meetings during the event. The virtual presentation is scheduled from 10:00 to 10:30 ET. Interested parties can access the webcast through Aptose's website or directly via a provided link. Aptose specializes in developing personalized oncology therapies, currently focusing on treatments for hematologic malignancies, including two investigational products in clinical trials.

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) will participate in two key biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference (January 10-13) and the 11th Annual LifeSci Partners Corporate Access Event (January 5-7). The management team will host investor meetings at both events. Aptose focuses on developing innovative cancer therapies, with products like HM43239 and luxeptinib aimed at treating hematologic malignancies. For more details, visit www.aptose.com.

Aptose Biosciences Inc. (NASDAQ: APTO) announced the discontinuation of clinical development for APTO-253, following an internal review and a clinical hold from the FDA. The focus will shift to advancing their kinome inhibitor pipeline, specifically HM43239 and luxeptinib, which have shown promising clinical activity in hematologic malignancies. The company is exploring strategic alternatives for APTO-253. This decision underlines Aptose's commitment to addressing unmet medical needs in oncology.

Aptose Biosciences has reported promising results for its oral myeloid kinome inhibitor HM43239, presented at the 2021 ASH Annual Meeting. The drug showed durable activity in patients with relapsed or refractory acute myeloid leukemia (AML). Key highlights include a 37.5% complete response rate among FLT3 mutant patients at the 80 mg dose. The Phase 1/2 trial enrolled 34 patients, showing a favorable safety profile. Additionally, data for luxeptinib and APTO-253 were shared, showcasing their potential in treating hematologic malignancies. Aptose aims to expand its clinical portfolio significantly.

Aptose Biosciences Inc. (NASDAQ: APTO) provided an update on its clinical developments on November 29, 2021, ahead of its corporate presentation on December 13, 2021. The presentation will highlight data from the oral Phase 1/2 trial of HM43239, an oral myeloid kinome inhibitor targeting relapsed or refractory acute myeloid leukemia (AML). Additionally, the status of luxeptinib, a dual lymphoid and myeloid kinome inhibitor, will be discussed. Both compounds are part of Aptose's continued commitment to advancing therapies for unmet needs in oncology.

Aptose Biosciences (Nasdaq: APTO; TSX: APS) announced its participation in the virtual Piper Sandler 33rd Annual Healthcare Conference, scheduled from November 23 to December 2, 2021. The company will present a pre-recorded fireside chat, which will be accessible on the conference website and through Aptose's official site. Additionally, management will engage in 1-on-1 investor meetings during the event. Aptose focuses on personalized oncology therapies, with a pipeline that includes three clinical-stage products targeting hematologic malignancies.

Aptose Biosciences reported a net loss of $11.3 million for Q3 2021, a decrease from $13.2 million in Q3 2020. Total cash as of September 30, 2021, was $95.1 million, projected to fund operations into early 2023. The company advanced its pipeline with HM43239, a myeloid kinome inhibitor, and increased the dose of Luxeptinib in ongoing clinical trials. Significant reductions in general and administrative expenses were observed. Aptose plans a conference call at 5 PM ET today to discuss these results.

Aptose Biosciences (NASDAQ: APTO) announced the acceptance of clinical data for its myeloid kinome inhibitor HM43239 for oral presentation at the 63rd ASH Annual Meeting in December 2021.

Additionally, data for Luxeptinib and APTO-253 have been accepted for poster presentations. The oral presentation is scheduled for December 13, 2021, while poster presentations will occur on December 11 and 13.

The presentations will feature new data and an investor event will provide further details.